- |||||||||| Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR: PSY_HaEMOPEQ: Effectiveness of Psychological Interventions in Haemophilia (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=20, Active, not recruiting, Not yet recruiting --> Active, not recruiting | N=66 --> 20 | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: GOCAPXE: What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum (clinicaltrials.gov) - Jun 28, 2018
P=N/A, N=23, Completed, Not yet recruiting --> Active, not recruiting | N=66 --> 20 | Trial completion date: Jan 2018 --> Dec 2018 | Trial primary completion date: Jan 2018 --> Dec 2018 Recruiting --> Completed | N=17 --> 23 | Trial completion date: Jun 2017 --> Dec 2017 | Trial primary completion date: May 2017 --> Dec 2017
- |||||||||| aspirin / Generic mfg.
Trial completion, Enrollment change: High-Shear Microfluidic Thrombosis Assay (clinicaltrials.gov) - Jun 7, 2018 P=N/A, N=16, Completed, Trial completion date: Dec 2019 --> Dec 2022 | Trial primary completion date: Sep 2017 --> Dec 2021 Enrolling by invitation --> Completed | N=45 --> 16
- |||||||||| Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma (clinicaltrials.gov) - Jun 2, 2018 P1, N=30, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| autologous CD34+ cells transduced with WASP lentiviral vector / Genethon, Boston Children's Hospital
Trial completion, Gene therapy: Gene Therapy for WAS (clinicaltrials.gov) - Jun 2, 2018 P1/2, N=5, Completed, Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| bortezomib / Generic mfg., melphalan / Generic mfg.
Trial completion, Trial completion date: Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Jun 1, 2018 P1/2, N=11, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2018 --> Feb 2018
- |||||||||| melphalan / Generic mfg., carfilzomib / Generic mfg., bendamustine / Generic mfg.
Enrollment closed: Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma (clinicaltrials.gov) - Apr 18, 2018 P1, N=26, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| gandotinib (LY 2784544) / Eli Lilly
Trial completion, Trial completion date: A Study in Myeloproliferative Disorders (clinicaltrials.gov) - Apr 17, 2018 P1, N=80, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2018
- |||||||||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion, Enrollment change, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - Apr 11, 2018 P=N/A, N=272, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Feb 2018 Active, not recruiting --> Completed | N=1482 --> 272
- |||||||||| Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Apr 11, 2018 P1, N=34, Completed, Active, not recruiting --> Completed | N=1482 --> 272 Active, not recruiting --> Completed | N=60 --> 34
- |||||||||| Trial completion date, Trial primary completion date: HeL-Fascial: Fascial Therapy in Elbow Hemophilic Arthropathy (clinicaltrials.gov) - Apr 10, 2018
P=N/A, N=60, Recruiting, Active, not recruiting --> Completed | N=60 --> 34 Trial completion date: Oct 2018 --> Feb 2019 | Trial primary completion date: May 2018 --> Dec 2018
- |||||||||| Phase classification, Enrollment change: Studies of Heritable Disorders of Connective Tissue (clinicaltrials.gov) - Apr 6, 2018
P, N=929, Completed, Recruiting --> Terminated; Terminated by sponsor Phase classification: P=N/A --> P | N=1335 --> 929
- |||||||||| Phase classification, Enrollment change: Genetic Susceptibility to Factor VIII Inhibitors (clinicaltrials.gov) - Apr 6, 2018
P, N=1187, Completed, Phase classification: P=N/A --> P | N=1335 --> 929 Phase classification: P=N/A --> P | N=3500 --> 1187
- |||||||||| staphylococcal protein A (PRTX-100) / Protalex
Trial completion date, Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Apr 5, 2018 P1b, N=30, Recruiting, Phase classification: P=N/A --> P | N=130 --> 73 Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018
- |||||||||| vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Vinorelbine and Gemcitabine in Myeloma (clinicaltrials.gov) - Apr 3, 2018 P2, N=136, Completed, Trial completion date: May 2018 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Sep 2018 Active, not recruiting --> Completed
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion date: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Mar 31, 2018 P2, N=21, Active, not recruiting, N=222 --> 21 | Recruiting --> Terminated Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Phase classification: Genetic Analysis of Gray Platelet Syndrome (clinicaltrials.gov) - Mar 30, 2018
P, N=123, Completed, Trial completion date: Dec 2017 --> Dec 2018 Phase classification: P=N/A --> P
- |||||||||| Trial completion, Enrollment change: PTI PARI: Study of Immune Thrombocytopenia Pathogenesis: (clinicaltrials.gov) - Mar 15, 2018
P=N/A, N=89, Completed, Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | N=175 --> 89
|